Form D · Biotechnology
Nasus Pharma Ltd
Tel Aviv, L3 · CIK 0002029039
Offering snapshot reported Feb 25, 2026 · SEC filing
- Reported sold
- $15M Offering amount: $15M
- Investors reported
- 15 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Feb 10, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Feb 25, 2026 | Initial | $15,000,040 | No comparison | 15 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $900K
- Finders' fees
- $0
- Form D file number
- 021-574660
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| CITIZENS JMP SECURITIES, LLC | 000022208 | |
| Laidlaw & Company (UK) Ltd. | 000119037 |
Source: Form D, filed Feb 25, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Udi Gilboa | Director |
| Ronnie Hershman | Director |
| Isaac Israel | Director |
| Dalia Megiddo | Director, Executive |
| Eyal Rubin | Executive |
| Sharon Shacham | Director |
| David Silberman | Director |
| Dan Teleman | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
34 Yitzhak Sadeh St
Tel Aviv, L3, 6274711
Tel Aviv, L3, 6274711